Condition: Multiple Myeloma · Sponsor: Nanjing IASO Biotechnology Co., Ltd.
This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomid-refractory RRMM who have received 1-2 lines of prior therapy.
This description comes directly from the study's public registry record.
Yue Wan · +86 025-58287610 · yue.wan@iasobio.com
Always discuss trial participation with your own doctor first.
| Beijing Chao-Yang Hospital, Capital Medical University | Beijing, China | Recruiting |
| Beijing GoBoard Boren Hospital | Beijing, China | Recruiting |
| Fu Xing Hospital, Capital Medical University | Beijing, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| Peking University Third Hospital | Beijing, China | Recruiting |
| People's Hospital of Peking University | Beijing, China | Recruiting |
| The first hospital of Jilin University | Changchun, China | Recruiting |
| West China School of Medicine, West China Hospital of Sichuan University | Chengdu, China | Recruiting |
| Xinqiao Hospital of AMU | Chongqing, China | Recruiting |
| Nanfang Hospital, Southern Medical University | Guangzhou, China | Recruiting |
| Sun Yat-sen University Cancer Centre | Guangzhou, China | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06464991